NASDAQ$ABUS
Arbutus Biopharma Corp · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Arbutus reported first quarter 2020 financial results and provided a pipeline update.
Arbutus Biopharma reported a net loss attributable to common shares of $16.8 million, or $0.25 per share, for the first quarter of 2020. The company's cash, cash equivalents, and investments totaled $88.1 million as of March 31, 2020, which is expected to fund operations into mid-2021. Arbutus is advancing its clinical trials and preclinical research, including a new research initiative to identify novel antiviral therapies for COVID-19.
- Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges.
- Preliminary results from an ongoing Phase 1a/1b clinical trial for AB-729 demonstrate that it is a potent RNAi agent capable of reducing HBsAg plasma levels.
- Arbutus initiated an internal research program to identify new small molecule antiviral medicines to treat COVID-19 and future coronavirus outbreaks.
- Arbutus had cash, cash equivalents and investments totaling $88.1 million as of March 31, 2020, sufficient to fund operations into mid-2021.
Headline financials
Revenue & EPS history
Arbutus · Revenue · Quarterly
$1.49M
Revenue by segment
Arbutus · $1.49M total across 2 segments · Q1 2020
- Collaborations & Licenses$835K+64.4%56.0%
- Non-cash Royalty Revenue$656K+283.6%44.0%
Forward guidance
Arbutus provided forward-looking statements regarding the timing and clinical development of its product candidates, expectations for data availability, planned 2020 objectives and cash burn guidance, potential safety and efficacy of product candidates, expectations for research efforts to combat COVID-19, and the expected sufficiency of cash to fund operations.
Tailwinds
- Certain data from the 60 mg single-dose cohort will be available in the second quarter of 2020.
- Results from the multi-dose 60 mg and single-dose 90 mg cohorts will be available in the second half of 2020.
- IND-enabling studies for AB-836 will be complete by the end of 2020.
- Arbutus expects AB-836 to have increased potency and an enhanced resistance profile compared to AB-506.
- Ending first quarter cash, cash equivalents and investments are expected to be sufficient to fund operations into mid-2021.
Headwinds
- Pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated.
- Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products.
- Economic and market conditions may worsen.
- Market shifts may require a change in strategic focus.
- The ongoing COVID-19 pandemic could significantly disrupt clinical development programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2020
-1.3%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+0.1%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+22.2%
Q1 2020
Best reaction
-18.6%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +0.0% | -3.2% | — | |
| Q3 2025 | -5.8% | -8.1% | -2.7% | |
| Q2 2025 | +1.8% | -1.8% | +23.2% | |
| Q1 2025 | -0.9% | -1.9% | +10.7% | |
| Q4 2024 | -2.4% | +3.9% | -1.8% | |
| Q3 2024 | -5.8% | -5.8% | -7.1% | |
| Q2 2024 | -0.8% | -4.0% | +2.7% | |
| Q1 2024 | +0.7% | +5.6% | +24.9% | |
| Q4 2023 | -3.1% | -7.3% | -10.4% | |
| Q3 2023 | -0.5% | -5.9% | +10.6% | |
| Q2 2023 | +2.9% | -2.4% | -1.4% | |
| Q1 2023 | +3.6% | +4.0% | +2.8% | |
| Q4 2022 | +1.8% | +4.3% | +7.8% | |
| Q3 2022 | +0.8% | +7.3% | +6.1% | |
| Q2 2022 | +2.8% | +0.0% | -10.2% | |
| Q1 2022 | +1.6% | -20.5% | +8.4% | |
| Q4 2021 | -9.1% | -6.8% | -0.3% | |
| Q3 2021 | -9.6% | -9.1% | +7.8% | |
| Q2 2021 | +9.1% | +13.8% | +23.6% | |
| Q1 2021 | -15.9% | -20.2% | -11.5% | |
| Q4 2020 | -9.3% | -1.1% | -5.8% | |
| Q3 2020 | -8.8% | +5.9% | +31.0% | |
| Q2 2020 | -16.2% | -18.5% | -44.2% | |
| Q1 2020 | +22.2% | +55.6% | +37.0% | |
| Q4 2019 | -2.0% | -8.3% | -70.0% | |
| Q3 2019 | -4.0% | -3.4% | +53.7% | |
| Q2 2019 | +1.2% | +1.2% | -11.0% | |
| Q1 2019 | -5.4% | -10.0% | -36.4% | |
| Q4 2018 | -8.0% | +2.7% | +9.5% | |
| Q3 2018 | +13.7% | -6.7% | -7.4% | |
| Q2 2018 | -18.6% | -19.4% | -23.2% | |
| Q1 2018 | +3.5% | +8.8% | +7.0% | |
| Q4 2017 | -12.5% | -17.5% | -13.3% | |
| Q3 2017 | +20.4% | +4.6% | +2.8% | |
| Q2 2017 | -4.2% | +1.4% | +15.3% | |
| Q1 2017 | -2.4% | -0.9% | +2.1% | |
| Q4 2016 | -6.0% | -4.5% | +0.0% | |
| Q3 2016 | -3.3% | -4.9% | -12.1% | |
| Q2 2016 | -8.6% | -13.6% | -14.5% | |
| Q1 2016 | -3.8% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -2.3% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -5.1% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2013 | -3.1% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +0.6% | — | — | |
| Q2 2012 | -0.3% | — | — | |
| Q1 2012 | -5.1% | — | — | |
| Q4 2010 | +2.9% | — | — | |
| Q4 2011 | +2.9% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | -4.1% | — | — | |
| Q3 2010 | +0.8% | — | — | |
| Q2 2010 | -0.8% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro